BASEL, Switzerland, Feb. 28, 2014 (GLOBE NEWSWIRE) -- Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today the amendment as of February 27, 2014 of the isavuconazole License, Co-Development and Co-Promotion Agreement with Astellas Pharma Inc. originally executed in 2010, providing Basilea full rights to isavuconazole in all markets outside of the U.S. and Canada in return for Basilea’s right to co-promote the product in the U.S. and Canada and its right to receive payments related to co-promotion and EU milestone payments.
Help employers find you! Check out all the jobs and post your resume.
